IP Library Granted Patent US 10,870,672
Granted Patent B2
US 10,870,672 · App. 16/900,397 · Granted Dec 22, 2020

β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

Inventors: Jean-Pierre Sommadossi (Boston, MA); Adel Moussa (Burlington, MA)
Assignee: Atea Pharmaceuticals, Inc.
C07H19/207A61K31/7076A61P31/14C07H19/16C07H19/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,870,672
App. No.
16/900,397
Granted
Dec 22, 2020
Kind
B2
Abstract

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims (43)

1. A pharmaceutical composition comprising an effective therapeutic amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 1 , comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition of claim 1 , in a dosage form.

5. The pharmaceutical composition of claim 4 , in a solid dosage form.

6. The pharmaceutical composition of claim 5 , in a solid oral dosage form.

7. The pharmaceutical composition of claim 6 , in a tablet.

8. The pharmaceutical composition of claim 6 , in a capsule.

9. The pharmaceutical composition of claim 2 , in a dosage form.

10. The pharmaceutical composition of claim 9 , in a solid dosage form.

11. The pharmaceutical composition of claim 9 , in a solid oral dosage form.

12. The pharmaceutical composition of claim 11 , in a tablet.

13. The pharmaceutical composition of claim 11 , in a capsule.

14. The pharmaceutical composition of claim 3 , in a dosage form.

15. The pharmaceutical composition of claim 14 , in a solid dosage form.

16. The pharmaceutical composition of claim 14 , in a solid oral dosage form.

17. The pharmaceutical composition of claim 16 , in a tablet.

18. The pharmaceutical composition of claim 16 , in a capsule.

19. A pharmaceutical composition comprising an effective therapeutic amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

20. The pharmaceutical composition of claim 18 , comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof.

21. The pharmaceutical composition of claim 18 , comprising a compound of the

formula:

or a pharmaceutically acceptable salt thereof.

22. The pharmaceutical composition of claim 19 , in a dosage form.

23. The pharmaceutical composition of claim 22 , in a solid dosage form.

24. The pharmaceutical composition of claim 22 , in a solid oral dosage form.

25. The pharmaceutical composition of claim 24 , in a tablet.

26. The pharmaceutical composition of claim 24 , in a capsule.

27. The pharmaceutical composition of claim 20 , in a dosage form.

28. The pharmaceutical composition of claim 27 , in a solid dosage form.

29. The pharmaceutical composition of claim 27 , in a solid oral dosage form.

30. The pharmaceutical composition of claim 29 , in a tablet.

31. The pharmaceutical composition of claim 29 , in a capsule.

32. The pharmaceutical composition of claim 21 , in a dosage form.

33. The pharmaceutical composition of claim 32 , in a solid dosage form.

34. The pharmaceutical composition of claim 32 , in a solid oral dosage form.

35. The pharmaceutical composition of claim 34 , in a tablet.

36. The pharmaceutical composition of claim 34 , in a capsule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2020
From: SOMMADOSSI, JEAN-PIERRE; MOUSSA, ADEL
To: ATEA PHARMACEUTICALS, INC.
Reel/Frame 053030/0202 →
Continuity (8)
Continuation 16278621 · Feb 18, 2019
Continuation 16001549 · Jun 6, 2018
Continuation 15782628 · Oct 12, 2017
Continuation 15063461 · Mar 7, 2016
Provisional Application 62276597 · Jan 8, 2016
Provisional Application 62253958 · Nov 11, 2015
Provisional Application 62129319 · Mar 6, 2015
Related Publication 20200308215A1 · Oct 1, 2020
Cited By (2)
US 12,458,656 US 12,551,499